CCR9 and neoplasm: Our experience with an anti-CCR9 antibody has demonstrated that a combination of suboptimal doses of the antibody in combination with suboptimal doses of vincristine led to a synergistic increase in survival of the xenotransplanted mice, where 40% of them survived >440 days with undetectable tumor cells in the spleen, bone marrow, or liver [83].